Survival and glycemic control in patients with coexisting lymphoma and diabetes: a case-control analysis

Bria J Rice; Matthew R Buras; Heidi E Kosiorek; Kyle E Coppola; Shailja B Amin; Patricia M Verona; Curtiss B Cook; Nina J Karlin

doi:10.2144/fsoa-2020-0100

Survival and glycemic control in patients with coexisting lymphoma and diabetes: a case-control analysis

Future Sci OA. 2020 Oct 27;7(1):FSO641. doi: 10.2144/fsoa-2020-0100.

Authors

Bria J Rice¹, Matthew R Buras², Heidi E Kosiorek², Kyle E Coppola³, Shailja B Amin⁴, Patricia M Verona⁵, Curtiss B Cook⁶, Nina J Karlin^{3

4}

Affiliations

¹ Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.
² Department of Biostatistics, Mayo Clinic, Scottsdale, AZ 85259, USA.
³ Mayo Clinic Cancer Center, Mayo Clinic, Scottsdale, AZ 85259, USA.
⁴ Division of Hematology & Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
⁵ Department of Information Technology, Mayo Clinic, Scottsdale, AZ 85259, USA.
⁶ Division of Endocrinology, Mayo Clinic, Scottsdale, AZ 85259, USA.

Abstract

Aim: We examined the effect of diabetes on survival in patients with lymphoma and the effect of lymphoma on glycemic control.

Patients & methods: Patients with lymphoma with and without diabetes (2005-2016) were retrospectively identified and matched 1:1. Overall survival and progression-free survival were estimated by the Kaplan-Meier method. Hemoglobin A_1c (HbA_1c) and glucose levels during the year after cancer diagnosis were compared by mixed models.

Results: For patients with diabetes, mean HbA_1c during the year after lymphoma diagnosis was 6.7%. Estimated 5-year progression-free survival for patients with versus without diabetes was 63% (95% CI: 53-76%) versus 58% (95% CI: 46-71%) (p = 0.42).

Conclusion: Lymphoma and its treatment did not affect glycemic control. Diabetes did not decrease lymphoma-specific survival.

Keywords: cancer; diabetes; endocrinology; lymphoma; outcomes research; survival.